Shangda Superalloys (301522.SZ) has received a long-term supply confirmation letter from a leading overseas aviation company.
Shangda Corporation (301522.SZ) announced that on December 22, 2025, the company received a long-term supply confirmation letter from a leading overseas aerospace company (referred to as "overseas customer"). Based on this confirmation letter, the overseas customer will purchase designated high-temperature alloy materials from the company for the period of 2026-2030. The total order amount is approximately 100 million yuan in high-temperature alloy products for the aerospace sector.
Shangda Superalloys (301522.SZ) announced that on December 22, 2025, the company received a long-term supply confirmation letter from a leading overseas aviation company (hereinafter referred to as "the overseas customer"). Based on this confirmation letter, the overseas customer will purchase the company's specified high-temperature alloy materials during the period from 2026 to 2030. The total order amount is approximately 100 million yuan in high-temperature alloy products for the aviation industry.
Related Articles
Maiwei Biological (688062.SH): The clinical trial application for 9MW1911 injection has been approved by the FDA.
On December 23rd, BEISEN HOLDING (09669) spent 1.3298 million Hong Kong dollars to repurchase 182,000 shares.
Goldwind Science & Technology's shareholder Harmony Health has reduced its holding in the company by approximately 31.89 million shares.
Maiwei Biological (688062.SH): The clinical trial application for 9MW1911 injection has been approved by the FDA.
On December 23rd, BEISEN HOLDING (09669) spent 1.3298 million Hong Kong dollars to repurchase 182,000 shares.
Goldwind Science & Technology's shareholder Harmony Health has reduced its holding in the company by approximately 31.89 million shares.
RECOMMEND
